Research

Clues to COVID-19 coronavirus's vulnerability emerge from an antibody against SARS

An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the new coronavirus at the root of COVID-19, according to a study from scientists at Scripps Research.

The study, published today in Science, is the first to map a human antibody's interaction with the new coronavirus at near-atomic-scale resolution.

Experimental AI tool predicts which COVID-19 patients develop respiratory disease

An artificial intelligence tool accurately predicted which patients newly infected with the COVID-19 virus would go on to develop severe respiratory disease, a new study found. The work was led by NYU Grossman School of Medicine and the Courant Institute of Mathematical Sciences at New York University, in partnership with Wenzhou Central Hospital and Cangnan People's Hospital, both in Wenzhou, China.

Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)

Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo announced these new findings on March 18, 2020.

Singapore modelling study estimates impact of physical distancing on reducing spread of COVID-19

A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (for infected individuals and their families), school closure, and workplace distancing, is most effective at reducing the number of SARS-CoV-2 cases compared with other intervention scenarios included in the study.

CAR macrophages go beyond T cells to fight solid tumors

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Perelman School of Medicine at the University of Pennsylvania may have an alternative to T cell therapy that can overcome those challenges.

Vivli to launch a portal for sharing data from COVID-19 trials

In a visible sign of data sharing leadership, Vivli, the Center for Clinical Research Data has committed to serving the open science community through the launch of a COVID-19 portal for sharing of completed interventional treatment trial data. All member and user fees would be waived for sharing and access.

Understanding how COVID-19 affects children vital to slowing pandemic

Though COVID-19 so far appears to be largely sparing children, researchers are cautioning that it is critical to understand how the virus affects kids to model the pandemic accurately, limit the disease's spread and ensure the youngest patients get the care they need.

Clues to COVID-19 coronavirus's vulnerability emerge from an antibody against SARS

Experimental AI tool predicts which COVID-19 patients develop respiratory disease

Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)

Singapore modelling study estimates impact of physical distancing on reducing spread of COVID-19

CAR macrophages go beyond T cells to fight solid tumors

Vivli to launch a portal for sharing data from COVID-19 trials

Understanding how COVID-19 affects children vital to slowing pandemic

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs